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ABSTRACT
Systematic analysis of the RNA-protein interactome
requires robust and scalable methods. We here
show the combination of two completely orthog-
onal, generic techniques to identify RNA-protein
interactions: PAR-CLIP reveals a collection of
RNAs bound to a protein whereas SILAC-based
RNA pull-downs identify a group of proteins bound
to an RNA. We investigated binding sites for five dif-
ferent proteins (IGF2BP1-3, QKI and PUM2) exhibit-
ing different binding patterns. We report near
perfect agreement between the two approaches.
Nevertheless, they are non-redundant, and ideally
complement each other to map the RNA-protein
interaction network.
INTRODUCTION
Messenger RNAs (mRNAs) are bound by RNA-binding
proteins that determine their localization, stability and
translational efﬁciency. In the last decade, introduction
of systematic and global methodologies have greatly
improved our knowledge of the nature and the complexity
of mRNA-protein interactions. In particular, protein-
centric methods, in which the protein of interest is
immunoprecipitated by an antibody and the interacting
RNAs identiﬁed on a transcriptome-wide scale by micro-
array hybridization (RIP-chip) or next-generation
sequencing (RIP-seq), have uncovered a complex target
recognition pattern for RNA-binding proteins (1–3).
Photoactivatable-Ribonucleoside-Enhanced Crosslinking
and Immunoprecipitation (PAR-CLIP), a recently de-
veloped technique, uses 4-thiouridine (4SU) to label
mRNAs in vivo combined with UV-crosslinking to
improve recovery and to facilitate the identiﬁcation of
the crosslinking site (4). However, in all these approaches
technical parameters inﬂuence the identiﬁcation of binding
sites (5) and there is no complete overlap between individ-
ual experiments and sometimes low overlap between dif-
ferent laboratories.
In RNA-centric methods, the discovery of proteins
interacting with a selected RNA is commonly performed
by mass spectrometry (MS). In most cases, the proteins
bound to an RNA are selected for MS analysis by visual
inspection of stained sodium dodecyl sulphate (SDS)
gels. We recently increased throughput and enabled
streamlined systematic studies using a quantitative prote-
omics method based on stable isotope labeling of amino
acids in cell culture (SILAC). That approach allows for
the discovery of RNA-binding proteins speciﬁcally bound
to an RNA recognition element (RRE) embedded within a
longer RNA fragment interacting with a large number of
unspeciﬁc binding proteins (6). However, systematic
studies require the conﬁdent identiﬁcation of proteins in
complex mixtures, which still presents a challenge in many
mass spectrometric laboratories (7). Apart from our
previous study on a 30-UTR fragment of HDAC2 (6), a
similar quantitative MS-based concept has also been used
to characterize proteins binding to the untranslated region
(UTR) of viral DENV-2 (8). Recently, another group
reported the puriﬁcation of crosslinked MS2-tagged
ribonucleoproteins (RNPs) under denaturing conditions
using SILAC (9).
Although some factors in our previous study were
validated using other methods, we were particularly inter-
ested in how our quantitative in vitro RNA pull-down
approach compares to PAR-CLIP, another streamlined
and generic method to identify RNA-protein interactions.
Besides their intrinsic technical challenges, PAR-CLIP
and quantitative RNA pull-downs have additional but
not identical caveats due to the generic nature of these
approaches. In the absence of suitable antibodies,
PAR-CLIP is generally performed with overexpressed,
FLAG-tagged protein and 4SU-labeled RNA in vivo
followed by next-generation sequencing of the bound
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RNA fraction. In contrast, SILAC-based RNA
pull-downs are currently performed in vitro, but expose
non-modiﬁed RNA baits to endogenous protein levels.
Given these completely different approaches, RNA-
protein interactions that are common to them is very
likely to be true. Likewise, a strong overlap between




HeLa S3 cells were SILAC-labeled in RPMI 1640 (-Arg,
-Lys) medium containing 10% dialyzed fetal bovine serum
(Gibco) supplemented with 84mg/l 13C6
15N4 L-arginine
and 40mg/l 13C6
15N2 L-lysine (Eurisotop) or the corres-
ponding non-labeled amino acids, respectively. Three con-
secutive batches of cells were independently harvested and
cell extracts prepared as described by Dignam et al. (10).
For this study, the cytosolic fraction of this extraction
procedure was used.
Production of RNA templates
To create RNA templates, regions of interest were cloned
into pcDNA3.3 (Invitrogen) and ampliﬁed forward
primers containing the T7 promoter and reverse primers
with the minimal S1 aptamer sequence (11). The control
fragment was ampliﬁed from pDEST17 vector and also
subcloned into pcDNA3.3 whereas the IRE fragment
was constructed by primer extension (Supplementary
Table S1, Supplementary Figure S7). Polymerase chain
reaction (PCR) fragments (1 mg) were used in in vitro
run-off transcription using T7 RNA polymerase and
tagged RNA oligonucleotides were puriﬁed with G-50
micro spin columns (GE Healthcare). Successful in vitro
transcription was monitored by running an aliquot of the
reaction on a 10% denaturing polyacrylamide gel
(Rotiphorese), staining with ethidium bromide and subse-
quent UV detection. RNA concentration was determined
by UV absorbance measurement on a Nanodrop (Peqlab).
RNA pull-down
25 mg of S1-tagged RNA was bound to paramagnetic
streptavidin beads (Dynabeads C1, Invitrogen) in RNA
binding buffer (150mM NaCl, 50mM Hepes-HCl pH
7.5, 0.5% NP40 (v/v), 10mM MgCl2) and incubated on
a rotation wheel at 4C. Beads were washed three times
with RNA wash buffer containing 250mM NaCl, 50mM
Hepes-HCl pH 7.5, 0.5% NP40 and 10mM MgCl2 before
incubation at 4C for 30min with 400 mg of cytoplasmic
extract; 40 units RNase inhibitor (Fermentas) and 20 mg
yeast tRNA (Invitrogen). After incubation beads were
washed another three times with RNA wash buffer, frac-
tions combined and RNA was eluted from the beads with
buffer containing 16mM biotin. The ethanol-precipitated
supernatant was resuspended in 8M urea/50mM
ammonium bicarbonate pH 8 (Sigma) for subsequent
MS analysis.
MS data acquisition and data analysis
In-solution digestion and MS analysis was performed es-
sentially as previously described (6). Peptides were
desalted on StageTips and separated on a C18-reversed
phase column packed with Reprosil (Dr Maisch),
directly mounted on the electrospray ion source on a
Orbitrap mass spectrometer (Thermo Fisher Scientiﬁc).
We used a 120min gradient from 2% to 60% acetonitrile
in 0.5% acetic acid at a ﬂow of 200 nl/min. Measurements
were either performed on a LTQ-Orbitrap XL using CID
fragmentation or a Velos-Orbitrap using HCD fragmen-
tation (12) with a data-dependent Top10 MS/MS spectra
acquisition method per MS full scan in the Orbitrap
analyser. The raw ﬁles were processed with MaxQuant
(6,13) (version 1.0.11.5) and searched with the Mascot
search engine (version 2.2.04, Matrix Science) against
the IPI human v3.37 protein database concatenated with
a decoy of the reversed sequences. Carbamidomethylation
was set as ﬁxed modiﬁcation whereas methionine oxida-
tion and protein N-acetylation were considered as variable
modiﬁcations. The search was performed with an initial
mass tolerance of 7 ppm mass accuracy for the precursor
ion and 0.5 Da (CID) or 20 ppm (HCD) for the MS/MS
spectra. Search results were processed with MaxQuant
and identiﬁcation up to a false discovery rate of 0.01
were accepted. Prior to statistical analysis, known contam-
inants and reverse hits were removed. Only proteins
identiﬁed with at least two unique peptides and quantiﬁ-
cation events were considered for analysis.
Two-dimensional interaction plots were plotted in R
(prerelease version 2.8.0).
Overexpression of IGF2BP2
The IGF2BP2 gene sequence from the Orfeome Collection
(OCAAo5051F0895D) was recombined into a FLAG/
pcDNA3.1 gateway compatible expression vector. HeLa
cells were labeled in DMEM (-Arg, -Lys) medium contain-
ing 10 % dialyzed fetal bovine serum (Gibco) supple-
mented with 58mg/l 13C6
15N4 L-arginine and 34mg/l
13C6
15N2 L-lysine (Eurisotop) or the corresponding
non-labeled amino acids, respectively. One 10 cm dish
with around 7 million cells (80% conﬂuence) each for
light and heavy were transfected with FLAG/
pcDNA3.1/IGF2BP2 using Lipofectamine 2000 (Life
Technologies) according to the manufacturer’s instruc-
tions. Optimem medium (Life Technologies) containing
the complexes was replaced 4 hr after transfection by
light and heavy SILAC medium, respectively. After
24 hr, cells were trypsinized, harvested and cell extracts
were prepared as described in Dignam et al. (10).
RESULTS AND DISCUSSION
To compare the two technologies for RNA-protein
mapping in an unbiased way, we performed a blind
study with RNA regions selected by one group (Tuschl)
without prior knowledge of the binding proteins by the
other group (Mann). Five different RNA binding proteins
previously analysed by PAR-CLIP were chosen to repre-
sent different mRNA binding patterns (Supplementary
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Figure S8): these included the three members of the
IGF2BP family, QKI and PUM2. IGF2BP1-3 share the
same CAU RRE, often repeated on G-poor RNA
segments. The three members appear to have overlapping
target speciﬁcities, however, the variable sequencing depth
between PAR-CLIP experiments leads to incomplete
overlap, especially for less abundant mRNAs. QKI has
a well-deﬁned 6-nt RRE (AYUAAY). The last candidate,
PUM2, is part of a two-protein family in humans, which
share an 8-nt RRE (UGUANAUA). The three protein
families have distinct distributions of binding sites reﬂect-
ing their different subcellular localization and function.
IGF2BP and PUM proteins are predominantly cytoplas-
mic and their binding sites are predominantly found in
exons; however, while IGF2BP proteins distribute
binding sites about equally across coding sequence
(CDS) and UTR, PUM binding sites are almost exclu-
sively located in 30-UTRs. In contrast, the QKI protein
is predominantly nuclear and the majority of binding
sites are intronic; those sites that are exonic predominantly
distribute to the 30-UTR (4).
We designed fragments of around 100–150 bases
(Supplementary Table S2), which allows a natural
context of the binding site, but limits the number of
putative additional interaction sites for other RNA-
binding proteins in close vicinity. We ﬁrst focused on the
PTPN13 mRNA 30-UTR region (pos. 8050–8190), which
in PAR-CLIP experiments yielded binding sites for
IGF2BP1, IGF2BP2, IGF2BP3 and QKI (Figure 1A).
To ensure high speciﬁcity of the quantiﬁcation experi-
ments, the pull-downs were always conducted in duplicate
with switched isotope labels. Speciﬁc binders showing high
SILAC ratios in the forward pull-down (target sequence
BA
C
Figure 1. (A) RNA bait fragment of the PTPN13 mRNA (pos. 8050–8190) fused 50 of the S1-aptamer together with an overview of PAR-CLIP
reported RNA binding sites. (B) Example of a two-dimensional interaction plot for the pos. 8050–8190 PTPN13 mRNA fragment incubated with
HeLa wild-type extract. IGF2BP1, IGF2BP3 and QKI were previously reported to bind to this fragment. (C) Biological replicates show reproducible
enrichment of speciﬁc binding events in forward and reverse pull-down. IGF2BP2 is detected in the screen only when expressed ectopically.
-4 +40
enrichment (log2)
Figure 2. Heatmap of speciﬁcally enriched proteins in all replicates of
the PTPN13 mRNA (pos. 8050–8190) fragment shows eight proteins
with an enrichment pattern similar to IGF2BPs and QKI.
Nucleic Acids Research, 2012, Vol. 40, No. 19 9899
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incubated with heavy extract, control sequence incubated
with light extract) need to have a reciprocal value in the
reverse pull-down (target sequence incubated with light
extract, control sequence incubated with heavy extract)
(Supplementary Figure S1, Supplementary Table S3).
These experiments identiﬁed IGF2BP1, IGF2BP3 and
QKI as speciﬁc interactors to this fragment as compared
with an unrelated control RNA fragment. Furthermore,
these three proteins had some of the highest SILAC ratios
obtained in this data set (Figure 1B). We did not detect
binding of IGF2BP2 to this fragment. This is likely due to
its at least 10 times lower abundance in HeLa cells (14)
compared with IGF2BP1 and IGF2BP3 and dynamic
range limitations in the mass spectrometer in the
presence of highly abundant unspeciﬁc background
binders. As expected, speciﬁc IGF2BP2 binding was
readily detectable in lysates from cells overexpressing
FLAG-IGF2BP2 (Figure 1C, Supplementary Figure S2).
Additionally, we identiﬁed 11 other RNA-binding
proteins that were at least 2-fold enriched on our bait
PTPN13 RNA. Notably, eight of them are found in all
three independent replicates: the cold-shock domain
proteins YBX1 and CSDA, the complement factor
C1QBP, the heterogeneous nuclear particles HNRNPR
and HNRPQ, the heterodimer composed of ILF2 and
ILF3, and the double strand RNA binding protein
STRBP (Figure 2).
To eliminate any potential systematic effect of the
control fragment, we repeated the experiment with
another unrelated RNA fragment containing an iron
response element (IRE). This control fragment should spe-
ciﬁcally bind the IRE-binding proteins with inverted
SILAC ratios while still preserving detection of the
speciﬁc candidates at the PTPN13 mRNA fragment.
Indeed, we were able to enrich IGF2BPs and QKI on
the PTPN13 mRNA fragment (pos. 8050–8190) whereas
the IRE control sequence was bound by its known binding






Figure 3. (A) Representation of PAR-CLIP binding sites for JMJD1C mRNA: IGF2BPs (green), QKI (blue) and PUM2 (red). (B–E)
Two-dimensional interaction plots for four regions of the JMJD1C mRNA: (B) regions pos. 4900–5027 and (C) pos. 2581–2720 bind QKI and
IGF2BP family members. (D) A control region, which binds neither IGF2BP family members nor QKI or PUM2 in PAR-CLIP. (E) PUM2 is
detected as binder to the pos. 7255–7368 fragment harboring a PUM2 consensus binding site that was not occupied in PAR-CLIP.
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tested this IRE containing RNA fragment against itself,
IREB1 was detected with a SILAC ratio of around one
and no protein showed a SILAC ratio indicative of
speciﬁc binding (Supplementary Figure S4). To investigate
the reproducibility of our results, we performed the
pull-downs of PTPN13 mRNA fragment (pos. 8050–
8190) versus pDEST17 control fragment with extracts
derived from three independent cell populations. In all
three experiments we conﬁrmed that IGF2BP1 and 3, as
well as QKI, were speciﬁc binders as indicated by their
SILAC ratios (Figure 1C, Supplementary Figure S5).
Furthermore, while triplicates showed high reproducibility
for detection of the speciﬁc interactors, each single experi-
ment already unambiguously identiﬁed the binding
partners. To validate the interaction of PUM2, which
did not bind to the former PTPN13 mRNA fragment,
we chose the PDCD10 mRNA 30-UTR region (pos.
1274–1380) and readily identiﬁed PUM2 as a binder
(Supplementary Figure S6).
Having validated the approach for each of the ﬁve
proteins, we focused on the JMJD1C mRNA, which inter-
acts with all ﬁve proteins, but in different regions
(Figure 3A). The JMJD1C mRNA CDS fragment (pos.
4900–5027) (Figure 3B) and JMJD1C mRNA CDS
fragment (pos. 2581–2720) (Figure 3C) both bind
IGF2BP family members and QKI. Two further
JMJD1C CDS region (pos. 6491–6630 and pos. 7255–
7368) were selected as controls devoid of PAR-CLIP
binding sites. The SILAC assay showed no enrichment
for any of the tested proteins for the ﬁrst region (pos.
6491–6630) (Figure 3D), however, the second region
(pos. 7255–7368), which comprised a perfect PUM2 con-
sensus motif (UGUAAAUA) identiﬁed PUM2 as a
speciﬁc binder (Figure 3E). This was unanticipated,
given that PAR-CLIP revealed several PUM2 binding
sites located in the 30-UTR (222 reads in 5 clusters), and
none covering the PUM2 site located in the CDS region or
any other region in its CDS (4). Presumably in vivo,
PUM2 can only stably associate with the 30-UTR and
translation through the CDS prevents stable PUM2
binding.
In summary, our blind comparison of protein-centric
and RNA-centric methods for characterizing
RNA-protein binding found a nearly perfect overlap
between binding sites identiﬁed by PAR-CLIP and
SILAC-based RNA pull-downs, even in different cell
lines. We were able to validate nearly all interactions
detected by PAR-CLIP, which implies in vitro versus
in vivo reproducibility of the detected mRNA-protein
interactions and stability of mRNPs in our range of ex-
perimental conditions.
We reproducibly demonstrated the binding of 8 other
proteins to our PTPN13 mRNA fragment (pos. 8050–
8190) (Figure 2). The sequence stretch of 150 bases is
long enough to harbor additional RRE for these
proteins. As in the known case of IGF2BP family
members it is, however, also possible that RNA-binding
proteins recognize the same binding site and thus compete
for binding, which under the conditions of the RNA
pull-down will also result in their detection.
Furthermore, although most of the proteins have
RNA-binding domains, it cannot be ruled out that some
are recruited to the bait by secondary protein–protein
interactions. For example, we have previously used a
shorter 26 nt RNA bait containing the zip-code binding
sequence to identify IGF2BP1 and IGF2BP3 in an iden-
tical setup (6). In this experiment, we already co-puriﬁed
CSDA, YBX1 and C1QBP, which may have interacted via
protein–protein interactions, especially as YBX1 has pre-
viously been shown to be part of the CRD-mediated
mRNA stability complex (15). In such a situation,
PAR-CLIP can then be used to close the circle by
characterizing the binding characteristics of these proteins.
Despite the good overlap, the two methods are not re-
dundant: the protein-centric method will typically be used
when one is interested in the RNA binding proﬁle of a
particular protein whereas the RNA-centric method will
be used when one is interested in a particular RNA. These
complementary methods can then validate the found RRE
with high conﬁdence. The two technologies are well suited
for systematic analysis of mRNPs as they are orthogonal
of each other, use different experimental conditions,
do not rely on specialized reagents, and can be performed
quite rapidly for any protein or any RNA sequence.
We therefore propose the iterative use of these two
powerful technologies to map the mRNP interactome
(Figure 4).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
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Figure 4. PAR-CLIP reports transcriptome-wide binding sites for
RNA-binding proteins based on deep sequencing. These binding sites
can then be screened for additional mRNA-binding proteins by quan-
titative MS using PAR-CLIP data as positive control. Quantitative MS
identiﬁes the speciﬁc RNA-binding proteins from the endogenous
proteome, which can be targeted for immunoprecipitation and
analysis by PAR-CLIP for cross-validation.
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